Literature DB >> 11800471

Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

Ying Zhang1, Sallie Permar1, Zhonghe Sun1.   

Abstract

Pyrazinamide (PZA) is an important front-line anti-tuberculosis drug that is active only at acid pH. However, acid pH causes significant difficulty for PZA susceptibility testing. A common problem in PZA testing is false resistance caused by large bacterial inocula. This study investigated the relationship of false resistance to numbers of bacilli, pH and other factors that potentially affect susceptibility to PZA. Large inocula (10(7-8) bacilli/ml) of M. tuberculosis H37Ra caused significant increase in medium pH from 5.5 towards neutrality, and thus produced false resistance results. The increase in medium pH was determined to be a function of live bacilli; heat-killed bacilli had little or no effect. Susceptibility to PZA and its active derivative pyrazinoic acid (POA) was comparable on 7H11 agar medium, but POA was less active than PZA in liquid medium containing bovine serum albumin (BSA), suggesting that susceptibility to PZA or POA was reduced in the presence of BSA, because of its neutralising effect on medium pH and significant POA binding. A 3-month-old H37Ra culture was shown to be more susceptible to PZA exposure than a 4-day log-phase culture, suggesting that PZA is more active for non-growing bacilli. Finally, reserpine, an inhibitor of POA efflux pump, increased susceptibility to PZA even near neutral pH 6.8, with an MIC of 400 mg/L compared with 1,000 mg/L without reserpine. These findings should have implications for understanding the mode of action of PZA and for PZA susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11800471     DOI: 10.1099/0022-1317-51-1-42

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  94 in total

1.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

2.  Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?

Authors:  Jim Werngren; Erik Alm; Mikael Mansjö
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

3.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.

Authors:  Anthony D Baughn; Jiaoyu Deng; Catherine Vilchèze; Angelica Riestra; John T Welch; William R Jacobs; Oren Zimhony
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

5.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 6.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

7.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

8.  Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing.

Authors:  Melisa J Willby; Maria Wijkander; Joshua Havumaki; Kartee Johnson; Jim Werngren; Sven Hoffner; Claudia M Denkinger; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

9.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

10.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.